Bearing Point Capital LLC Buys Shares of 6,370 Gilead Sciences, Inc. (NASDAQ:GILD)

Bearing Point Capital LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,370 shares of the biopharmaceutical company's stock, valued at approximately $588,000.

Several other large investors have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC grew its holdings in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the sale, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at approximately $17,893,713.60. This trade represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 160,605 shares of company stock worth $16,718,136. 0.27% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GILD. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Finally, Morgan Stanley lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Down 1.3 %

Shares of NASDAQ:GILD traded down $1.30 during midday trading on Friday, hitting $96.86. 13,140,489 shares of the company's stock were exchanged, compared to its average volume of 7,599,780. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a market cap of $120.61 billion, a PE ratio of 261.78, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The stock has a 50 day moving average price of $107.23 and a 200-day moving average price of $99.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.32) earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.26%. Gilead Sciences's dividend payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.